This could facilitate the development of individualized medicine and offer novel insights into: 1) the role of comorbidities when interpreting discordant AD biomarkers and the outcomes of clinical trials; and 2) the potential of a standalone tau biomarker strategy in clinical routine. This evidence concerns the gene MAPT and Alzheimer disease.